Roubaix Capital’s Maravai LifeSciences MRVI Stock Holding History

Roubaix Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-237,747	Closed	-$1.98M	–	56
2024 Q3	$1.98M	Sell	237,747 -198,471	-45%	-$1.72M	1.09%	40
2024 Q2	$3.12M	Buy	+436,218	New	+$3.77M	1.97%	27
2023 Q3	–	Sell	-235,480	Closed	-$2.93M	–	51
2023 Q2	$2.93M	Buy	235,480 +52,841	+29%	+$713K	2.15%	24
2023 Q1	$2.56M	Buy	+182,639	New	+$2.62M	1.95%	25

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Roubaix Capital's MRVI Position: Q4 2024 in Review

Roubaix Capital sold out of Maravai LifeSciences (MRVI) in Q4 2024, closing a stake of 237,747 shares — an estimated $1.98M sold.

Roubaix Capital first reported a position in MRVI in Q1 2023 and held it in 4 quarters. The position peaked at $3.12M in Q2 2024. 185 funds tracked by Wall St. Rank hold MRVI as of Q4 2024.

Roubaix Capital reported no remaining Maravai LifeSciences position as of Q4 2024 after selling out during the quarter.
Roubaix Capital sold 237,747 Maravai LifeSciences shares in Q4 2024, an estimated $1.98M.
Roubaix Capital first reported a position in Maravai LifeSciences in Q1 2023 and held it in 4 quarters.
Roubaix Capital's Maravai LifeSciences position peaked at $3.12M in Q2 2024.
185 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2024.

Based on Roubaix Capital's 13F filing for Q4 2024, filed 13 Feb 2025.